Trial Profile
A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera Combined with Methotrexate in Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus First in man; Pharmacokinetics
- Sponsors Gedeon Richter
- 06 Jun 2018 Status changed from recruiting to completed.
- 28 Feb 2015 New trial record